文献速递腹部CTMR

慢性肝病的无创影像学生物标志物

Non-invasive imaging biomarkers in chronic liver disease.
PubMed 文献 · Eur J Radiol · 2024-09-18

本文综述慢性肝病无创影像评估进展,指出肝硬度测量与横断面成像(CT、MRI)可提供临床管理所需信息;MRI的PDFF序列可定量脂肪浸润,弹性成像(MRE)可检测和定量纤维化,IVIM、T1/T2 mapping及肝胆对比剂增强、影像组学是新兴方向。

要点

  • 肝硬度测量与CT/MRI横断面成像可在临床路径中辅助慢性肝病患者的治疗与随访。
  • CT和MRI均可计算肝表面结节度(LSN),其与慢性肝病及失代偿风险相关。
  • MRI的PDFF序列可定量脂肪肝浸润,MRE弹性成像可检测和定量肝纤维化。

核心结论

  • 无创检查已在慢性肝病临床路径中占据核心地位,肝硬度测量与横断面成像可为临床医生提供横向信息以辅助管理、治疗和随访患者。

研究设计与样本

  • 本文为综述,旨在全面概述有创与无创影像技术在慢性肝病评估和管理中的当前进展与应用。

关键影像表现/征象

  • CT和MRI均可计算肝表面结节度(LSN),其与慢性肝病及失代偿风险相关。
  • MRI的质子密度脂肪分数(PDFF)序列可定量脂肪肝浸润。
  • 磁共振弹性成像(MRE)可检测和定量肝纤维化。
  • IVIM、T1 mapping和T2 mapping等先进技术是检测纤维化沉积的有前景工具。
  • 注射肝胆对比剂不仅用于肝脏病灶定性,也用于评估肝功能,尤其在慢性肝病中。

临床应用与阅片要点

  • 肝硬度测量和横断面成像可提供辅助临床管理、治疗和随访慢性肝病患者的信息。
  • CT和MRI计算的肝表面结节度(LSN)与慢性肝病及失代偿风险相关。
  • MRI的PDFF序列可用于定量脂肪肝浸润,MRE可用于检测和定量肝纤维化。
  • IVIM、T1 mapping和T2 mapping是检测纤维化沉积的有前景工具。
  • 肝胆对比剂注射在慢性肝病中可用于评估肝功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Chronic liver disease (CLD) is a global and worldwide clinical challenge, considering that different underlying liver entities can lead to hepatic dysfunction. In the past, blood tests and clinical evaluation were the main noninvasive tools used to detect, diagnose and follow-up patients with CLD; in case of clinical suspicion of CLD or unclear diagnosis, liver biopsy has been considered as the reference standard to rule out different chronic liver conditions. Nowadays, noninvasive tests have gained a central role in the clinical pathway. Particularly, liver stiffness measurement (LSM) and cross-sectional imaging techniques can provide transversal information to clinicians, helping them to correctly manage, treat and follow patients during time. Cross-sectional imaging techniques, namely computed tomography (CT) and magnetic resonance imaging (MRI), have plenty of potential. Both techniques allow to compute the liver surface nodularity (LSN), associated with CLDs and risk of decompensation. MRI can also help quantify fatty liver infiltration, mainly with the proton density fat fraction (PDFF) sequences, and detect and quantify fibrosis, especially thanks to elastography (MRE). Advanced techniques, such as intravoxel incoherent motion (IVIM), T1- and T2- mapping are promising tools for detecting fibrosis deposition. Furthermore, the injection of hepatobiliary contrast agents has gained an important role not only in liver lesion characterization but also in assessing liver function, especially in CLDs. Finally, the broad development of radiomics signatures, applied to CT and MR, can be considered the next future approach to CLDs. The aim of this review is to provide a comprehensive overview of the current advancements and applications of both invasive and noninvasive imaging techniques in the evaluation and management of CLD.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Maino C, Vernuccio F, Cannella R, et al. Non-invasive imaging biomarkers in chronic liver disease. Eur J Radiol. 2024. PMID: 39317002. doi:10.1016/j.ejrad.2024.111749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。